COVID-19 Press Briefing

April 19, 2021
Daily Change in COVID-19 Cases, US
January 22, 2020 – April 17 2021

TOTAL Cases Reported Since 1/22/20
31,444,706

NEW Cases Reported to CDC on 4/17/21
60,947

Change in 7-Day Case Average
+1.1%

Current 7-Day Case Average (4/11/21 - 4/17/21)
67,443

Prior 7-Day Case Average (4/4/21 - 4/10/21)
66,702

Reported 7-day moving average* of COVID-19 cases has decreased 73% since January 11, 2021

Peaks in New Cases and Highest 7-Day Moving Average

<table>
<thead>
<tr>
<th></th>
<th>Highest Daily Number of New Cases</th>
<th>Highest 7-Day Moving Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current</td>
<td>315,006 (1/8/21)</td>
<td>249,861 (1/11/21)</td>
</tr>
<tr>
<td>2nd Peak</td>
<td>75,534 (7/17/20)</td>
<td>67,390 (7/21/20)</td>
</tr>
<tr>
<td>1st Peak</td>
<td>42,533 (4/6/20)</td>
<td>31,944 (4/12/20)</td>
</tr>
</tbody>
</table>
New Admissions of Patients with Confirmed COVID-19
August 1, 2020 – April 16, 2021

Patients Currently Hospitalized with COVID on 4/16/21
34,223

New Admissions on 4/16/21
5,317

Peak in New Admissions (1/5/21)
17,988

Change in 7-Day Average of New Admissions
+0.2%

Current 7-Day Average of New Admissions (4/10/21 - 4/16/21)
5,459

Prior 7-Day Average of New Admissions (4/3/21 - 4/9/21)
5,449

Reported 7-day moving average of hospitalizations has decreased 67% since January 9, 2021
Daily Change in COVID-19 Deaths, United States
January 22, 2020 – April 17, 2021

TOTAL Deaths Reported Since 1/22/2020
563,980

NEW Deaths Reported to CDC on 4/17/21
694

Change in 7-Day Death Average
+2.1%

Current 7-Day Death Average (4/11/21 - 4/17/21)
695

Prior 7-Day Death Average (4/4/21 - 4/10/21)
681

Forecasted Total Deaths by 5/8/21
574,000 to 598,000
COVID-19 Vaccination, United States
December 14, 2020 – April 18, 2021

Total Doses Delivered (12/14/20 - 4/18/21)
264,505,725

Total Doses Administered (12/14/20 - 4/18/21)
209,406,814

People Receiving ≥1 Dose (% Population)
131,247,546 (39.5%)

People Fully Vaccinated (% Population)
84,263,408 (25.4%)

Percent of People ≥65 Years Fully Vaccinated
65.9%

The four-day lag in reporting for which data is not complete is indicated by grey bars.
WEAR A MASK

STAY 6 FEET APART

AVOID CROWDS

AVOID TRAVEL
April 19, 2021

All those eligible for COVID-19 vaccines can get vaccinated
COVID-19 Vaccines are:

- Efficacious in clinical trials
- Effective in real-world settings
- Safe
COVID-19 Vaccines are:

- Efficacious in clinical trials
- Effective in real-world settings
- Safe
Pfizer/BioNTech Vaccine

The New England Journal of Medicine
Published online December 10, 2020

Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
FP Polack et al. for the C4591001 Clinical Trial Group

Efficacy: 95%

Moderna Vaccine

The New England Journal of Medicine
Published online December 30, 2020

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
LR Baden et al. for the COVE Study Group

Efficacy: 94.1%
Press Release

January 29, 2021

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Efficacy:
- 66% overall vs. moderate-to-severe COVID-19
  - 72% in U.S.
  - 66% in Latin America
  - 57% in South Africa
- 85% vs. severe disease across all regions studied
- Protection generally consistent across all age groups
COVID-19 Vaccines are:

- Efficacious in clinical trials
- Effective in real-world settings
- Safe
Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center

W Daniel, DK Podolsky et al.

- 23,234 employees of University of Texas Southwestern Medical Center, Dallas, TX; vaccination program initiated 12/15/2020
- 0.05% infection rate among fully vaccinated employees

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

- Prospective study; n=3,950
- mRNA vaccine effectiveness of full immunization (≥14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; 80% after one dose
- 3 PCR-confirmed infections occurred during 78,902 person-days with full immunization (0.04/1,000 person-days)
BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting

LN Dagan, RD Balicer et al.

- 600,000 newly vaccinated people and 600,000 matched controls in Israel

<table>
<thead>
<tr>
<th>Vaccine effectiveness</th>
<th>7 or more days after 2nd dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Documented infection</td>
<td>92%</td>
</tr>
<tr>
<td>Symptomatic COVID-19</td>
<td>94%</td>
</tr>
<tr>
<td>Severe disease</td>
<td>92%</td>
</tr>
</tbody>
</table>
Effect of Robust COVID-19 Vaccination Effort in Israel, Where B.1.1.7 Predominates

- **Vaccine doses**
- **Cases**

Source: Our World in Data
COVID-19 Vaccines are:

- Efficacious in clinical trials
- Effective in real-world settings
- Safe
Ensuring COVID-19 Vaccine Safety in the U.S.

- Clinical trials
- Expanded safety monitoring systems
  - CDC: V-safe
  - CDC: National Healthcare Safety Network (NHSN)
  - FDA: Other large insurer/payer databases
- Other safety monitoring systems
  - CDC and FDA: Vaccine Adverse Event Reporting System (VAERS)
  - CDC: Vaccine Safety Datalink (VSD)
  - CDC: Clinical Immunization Safety Assessment (CISA) Project
  - FDA and the Centers for Medicare and Medicaid Services: Medicare data
  - FDA: Biologics Effectiveness and Safety System (BEST)
  - FDA: Sentinel Initiative
  - DoD, FDA systems

Normalcy in America

Vaccines